Hepatitis C Virus Coinfection in a Cohort of HIV-Infected Individuals from Santos, Brazil: Seroprevalence and Associated Factors

AIDS Patient Care and STDs

Volumn 18, Issue 3, 2004, Pages 135-143

  Segurado, Aluisio Cotrim ^a,c   Braga, Patrícia ^a   Etzel, Arnaldo ^a,b   Cardoso, Maria Regina Alves ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b AIDS Reference Center   (Brazil)

^c AIDS Reference Center ^*  (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HEPATITIS C ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BRAZIL; COHORT ANALYSIS; COMORBIDITY; DRUG ABUSE; ENZYME IMMUNOASSAY; FEMALE; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREVALENCE; PROSTITUTION; RISK FACTOR; SAFE SEX; SEROPREVALENCE; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE; VIRUS TRANSMISSION;

ADULT; BRAZIL; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 1842457818     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729104322994829     Document Type: Article

References (37)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-362.
2. Alter MJ. Hepatitis C virus infection in the United States. J Hepatol 1999;31:(Suppl 1):88-91.
3. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000;20:1-16.
4. Alter M, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341: 556-562.
5. Lima MPJS, Pedro RJ, Rocha MDC. Prevalence and risk factors for hepatitis C virus (HCV) infection among pregnant Brazilian women. Int J Gynecol Obstet 2000;70:319-326.
6. Sulkowski MK, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis 2000;30:S77-84.
7. Stubbe L, Soriano V, Antunes F, et al. Hepatitis C in the EuroSIDA cohort of European HIV-infected patients: prevalence and prognostic value [abstract 22261]. In: Conference Record of the 12th World AIDS Conference (Geneva, Switzerland). Geneva: Marathon Multimedia, 1998.
8. Sasadeusz J. Human immunodeficiency virus-hepatitis C coinfection: swapping new problems for newer ones. Intern Med J 2001;31:418-421.
9. Mendes-Correa, MCJ, Barone AA, Guastini C. Hepatitis C virus seroprevalence and risk factors among patients with HIV infection. Rev Inst Med Trop S. Paulo 2000;43:15-19.
10. Burattini M, Massad E, Rozman M, Azevedo R, Carvalho H. Correlation between HIV and HCV in Brazilian prisoners: Evidence for parenteral transmission inside prison. Rev Saude Publica 2000;34:431-436.
11. Etzel A, Shibata GY, Rozman M, Jorge MLSG, Damas CD, Segurado AAC. HTLV-1 and HTLV-2 infections in HIV-infected individuals from Santos, Brazil: Seroprevalence and risk factors. J Acquir Immune Defic Syndr 2001;26:185-190.
12. Brazil Ministry of Health. Recomendações para a terapia anti-retroviral em adultos e adolescentes infectados pelo HIV-2002/2003. www.aids.gov.br/final/biblioteca/adulto_2002_2003/adulto.pdf
13. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Eng J Med 1998;338:853-860.
14. Brazil Ministry of Health. Boletim Epidemiológico de AIDS. Ano XV, no. 1, julho-setembro 2001. www.aids. gov.br/final/biblioteca/bol_set_2001/boletim.htm
15. Monga HK, Rodriguez-Barradas MC, Breaux K, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001;33:240-247.
16. Soriano V, Garcia-Samaniego J, Valencia E, Rodriguez-Rosado R, Munoz F, Gonzalez-Lahoz J. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 1999;15:1-4.
17. Brazil Ministry of Health. The experience of the Brazilian AIDS Programme. www.aids.gov.br/final/biblioteca/resposta/resp_ingles.pdf
18. Falusi OM, Pulvirenti J, Sarazine J, Shastri P, Gail G, Glowacki R. HIV-infected inpatients in the HAART era: How do hepatitis C virus coinfected patients differ? AIDS Patient Care STDs 2003;17:13-16.
19. Klein MB, Lalonde RG, Suissa S. The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003;33:365-372.
20. Di Martino V, Rufat P, Boyer N, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 2001;34: 1193-1199.
21. Carrilho FJ, Mendes-Correa, MCJ. The magnitude of hepatitis B and C in Latin America. In: Schinazi, RF, Sommadossi JP, Thomas HC, eds. Therapies for Viral Infection. London: International Medical Press, 1998:25-34.
22. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV cohort study. Lancet 2000;356:1800-1805.
23. Wasley A, Alter MJ. Epidemiology of hepatitis C: Geographic differences and temporal trends. Semin Liver Dis 2000;20:1-16.
24. Villano SA, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL. Incidence and risk factors for hepatitis C virus infections among injection drug users in Baltimore, Maryland. J Clin Biol 1997;74:3274-3277.
25. Koblin BA, Factor SH, Wu Y, Vlahov D. Hepatitis C virus infection among non injecting drug users in New York City. J Med Virol 2003;70:387-390.
26. Feldman JG, Minkoff H, Landesman S, Dehovitz J. Heterosexual transmission of hepatitis C, hepatitis B, and HIV-1 in a sample of inner city women. Sex Transm Dis 2000;27:338-342.
27. Giuliani M, Caprilli F, Gentili G, et al. Incidence and determinants of hepatitis C virus infection among individuals at risk of sexually transmitted diseases attending a human immunodeficiency virus type 1 testing program. Sex Transm Dis 1997;24:533-537.
28. Gordon SC, Patel AH, Kulesza GW, Barnes RE, Silverman AL. Lack of evidence for the heterosexual transmission of hepatitis C. Am J Gastroenterol 1992;87:1849-1851.
29. Tong MJ, Lai PPC, Hwang S-J, et al. Evaluation of sexual transmission in patients with hepatitis C infection. Clin Diagn Virol 1995;3:39-47.
30. Meisel H, Reip A, Faltus B, et al. Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin. Lancet 1995;345:1209-1211.
31. Armstrong BK, White E, Saracci R. Principles of Exposure Measurement in Epidemiology. Oxford: Oxford University Press, 1992.
32. Tumminelli F, Marcellin P, Rizzo S, et al. Shaving as potential source of hepatitis C virus infection [letter]. Lancet 1995;345:658.
33. Mastromatteo AM, Rapaccini GL, Pompili M, et al. Hepatitis C virus infection: other biological fluids than blood may be responsible for intrafamilial spread. Hepatogastroenterology 2001;48:193-196.
34. Cribier B, Schmitt, Rey D, et al. HIV increases hepatitis C viraemia irrespective of the hepatitis C virus genotype. Res Virol 1997;148:267-271.
35. Matthews-Greer JM, Caldito GC, Adley SD, et al. Comparison of hepatitis C viral loads in patients with or without human immunodeficiency virus. Clin Diagn Lab Immunol 2001;8:690-694.
36. Thomas DL, Villano SA, Riester KA, et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus-infected mothers. J Infect Dis 1998;177:1480-1488.
37. Pol S, Vallet-Pichard A, Fontaine H. Hepatitis C and human immunodeficiency coinfection at the era of highly active antiretroviral therapy. J Viral Hepatitis 2002;9:1-8.